Urinalysis Market Advancements In Urine Biomarkers For Disease Detection

The global urinalysis market size was valued at USD 2.14 billion in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 4.7% from 2023 to 2030. The market is witnessing growth due to factors including the rising incidence of diseases such as Urinary Tract Infections (UTIs), diabetes, and kidney diseases. For instance, according to the National Diabetes Statistics Report, 2020, around 34.1 million adults aged 18 years and above had diabetes in the U.S. About one-third of diabetic people have kidney-related comorbidities due to high blood sugar and blood pressure. Urinalysis is an informative and noninvasive diagnostic tool accessible to clinicians to diagnose kidney diseases. Hence, the rising prevalence of kidney ailments is anticipated to increase demand for products used in urinalysis, thereby driving market growth.

During the initial phase of the COVID-19 pandemic, the market for urinalysis was moderately impacted due to low hospitalization rates and declining sales of urine analysis tests. Nationwide lockdowns imposed by governments to control the spread of infection restricted people’s access to diagnostic and hospital services leading to low demand for diagnostics products. However, a resurgence in testing numbers is seen as countries eased restrictions on movement.

The growing importance of urinalysis for detecting post-COVID-19 diseases, such as acute kidney & tubular injuries, is anticipated to drive market growth. According to a study published by the Columbia University in 2021, kidney injury marker-1 (KIM-1) and urinary NGAL were two sensitive biomarkers for detecting tubular and kidney injury patients.

Gather more insights about the market drivers, restrains and growth of the Urinalysis Market

Detailed Segmentation: 

Product Insights

The consumables segment held the dominant market share of 78.61% in terms of revenue in 2022. This dominance can be attributed to the increasing demand and frequent purchases of reagents and dipsticks by clinical and hospital laboratories. Dipsticks are the most common type of consumable in urinalysis, accounting for the largest share of the market. Reagents measure the levels of specific substances in the urine. The development of new and innovative consumables, such as rapid test kits and point-of-care testing devices, makes urinalysis more accessible and convenient, which drives demand.

Application Insights

The urinary tract infection screening segment dominated the market and accounted for a revenue share of 25.06% in 2022, due to the rising incidence of UTIs worldwide. According to the National Center for Biotechnology Information (NCBI), around 150 million people suffer from urinary tract infections each year worldwide.On the other hand, the diabetes screening segment is expected to expand at the fastest CAGR of 7.3% during the forecast period. Urinalysis is an important screening test to find out about diabetes. According to the CDC, in 2022, around 37.3 million people in the U.S. will be affected by diabetes. Of these, about 28.7 million people are diagnosed, and 8.5 million are undiagnosed. Thus, the steadily increasing number of patients with diabetes acts as a major market driver.

End-use Insights

The clinical laboratories segment accounted for the highest revenue share of around 46.15% in 2022. This can be attributed to their easy accessibility to patients and the availability of advanced products in these laboratories. For instance, in the U.S., more than 20,000 clinical laboratories perform clinical tests, including urinalysis. New test methods have been used to improve the detection of kidney diseases, such as proteomics, genetic testing, microarrays, biomarkers, etc.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 38.3% in 2022. This dominance can be attributed to strategic initiatives undertaken by key players, such as licensing agreements, to expand their business footprint. For instance, in August 2020, Sysmex and Siemens Healthcare GmbH signed an exclusive licensing agreement to distribute and service the latter’s automated urine analyzer CLINITEK Novus to hospitals and reference laboratories in North America. Such agreements have had a positive impact on market growth.

Order a free sample PDF of the Urinalysis Market Intelligence Study, published by Grand View Research.